Key Points
Ahead of the listing, the company's shares are trading with a premium of Rs 22 in the unlisted market...
Considering the upper price band of Rs 140, the stock is likely to debut with a premium of 16%...
Valiant Labs is an active pharmaceutical ingredient (API)/bulk drug manufacturing company, with a focus on producing Paracetamol..
Investors might get a good listing benefit tomorrow (Friday), but they should also be cautious about related risks," said Shivani Nyati, Head of Wealth, Swastika Investmart...
The company's revenues grew 16% to Rs 339 crore in the fiscal year 2023, while net profit was marginally higher at Rs 28.9 crore, compared with Rs 27.4 crore a year ago...
You might be interested in
Avalon Technologies shares tumble 11% on listing day. Should you hold or sell?
18, Apr, 23The stock is currently trading nearly 8% down at Rs 396.90 on BSE. It hit the day's low of Rs 387.75, translating into a fall of 11% from IPO price. The tepid listing was expected after the downtrend in company shares in the unlisted market since the IPO opened for subscription. The issue was subscribed 2.21 times at close
3 IPOs under market regulator SEBI's scanner for inflating subscriptions
19, Jan, 24The development was confirmed by SEBI chairperson Madhabi Puri Buch at an event. She also said that the market regulator is working on measures to put an end to such malpractices.
Mamaearth IPO opens for subscription: Should you bid or skip?
31, Oct, 23The IPO of Mamaearth's parent company, Honasa Consumer Limited, has garnered mixed reaction from analysts. Here is all you need to know.
SIPs and SWPs combo to lead to the next big phase of investment: Prateek Pant, WhiteOak Capital AMC
08, May, 23India is attracting a lot of foreign institutional investors (FIIs) due to its unique position of being an outlier in uncertain global macroeconomics, according to Prateek Pant, Chief Business Officer at WhiteOak Capital AMC. Pant also said that India is well-positioned in terms of consumerism, capital growth and the health of the financial sector, making it attractive for investors seeing the potential of a 3-5 year investment.
Mamaearth IPO fully subscribed on Day 3 on QIB push. Check GMP and other details
02, Nov, 23The overall subscription was at 2.53 times so far, with QIB category leading the way at 4.12 times subscription. The retail and NII categories, however, are yet to reach full subscription. According to market sources, the company's shares are trading with a premium of Rs 9 in the unlisted market.
Valiant Laboratories shares list at 16% premium over issue price
06, Oct, 23Valiant Labs is an active pharmaceutical ingredient (API/bulk drug manufacturing company, with a focus on producing Paracetamol. APIs serve as raw materials for manufacturing finished dosage forms or formulations.
Valiant Laboratories IPO opens today. Should you subscribe to the issue?
27, Sep, 23The pharmaceutical API industry in India is ranked third-largest globally in terms of volume. It is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well as export markets.
2023 turns blockbuster year for Indian IPO mart! Can this euphoria last?
04, Aug, 23Analysts believe that the impressive rally in the secondary market has helped boost sentiment of the IPO market. Against a backdrop of global uncertainty and volatility the Indian stock market has come through as domestic indices, BSE Sensex and Nifty50, have jumped 8.76% and 8.55% year-to-date (YTD), respectively.
Concord Biotech shares list at 21% premium over IPO price
18, Aug, 23Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. The company is backed by Rakesh Jhunjhunwala's Rare Enterprises and another leading investment firm Quadria Capital Fund. Ahead of the listing, the company's shares commanded a premium of Rs 120 in the unlisted market.